PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Phase 2RecruitingNCT04144569

Yongchang Zhang30 enrolled

Overview

The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HER2 Insertion Mutation Positive Advanced NSCLC

Interventions

PD-1 Combined With PyrotinibDRUG

PD-1 Combined With Pyrotinib

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Advanced non-small cell lung cancer confirmed by histology or cytology * HER2 insertion mutation-positive * Failure with first-line standard chemotherapy * with measurable lesions. Exclusion Criteria: * no measurable tumor lesions * Patients received PD-1 or Pyrotinib before

Locations (1)

Hunan Provincal Tumor Hospital

Changsha, Hunan, China

RECRUITING

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: Approximately 1 years

Secondary Outcomes

ORR

To measure the patients's overall response rate

Time frame: Approximately 1 years

Overall survival

Time frame: Approximately 1 years

Central Contacts

Yongchang Zhang, MD

CONTACT

+8613873123436 zhangyongchang@csu.edu.cn

Xiangyu Zhang, PhD

CONTACT

514775505@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.